The upregulation of immune-related genes involved in PD-1/PD-L1 and T-cell cytotoxicity pathways, as observed in tumor samples of patients administered chemotherapeutic induction with doxorubicin, could account for the marked antitumor activity of doxorubicin, as hypothesized by the authors [76]. This evidence concerns the gene CD274 and neoplasm.